Close
Patheon
The Increasing Risks of Waiting to Address Solubility
Product Development
Tuesday, February 09, 2016

Under pressure to minimize costs and timelines during clinical development, it’s become common to put off solubility challenges. However, with 60%–90% of today’s new molecular entities presenting as insoluble, it makes sense to reconsider this strategy and its significant risks.


Please complete the short form below to download this asset.

Connect

We look forward to learning about your specific needs, please contact us.